CIBC Private Wealth Group’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,505
Closed -$11.9K 3442
2025
Q3
$11.9K Hold
1,505
﹤0.01% 2330
2025
Q2
$8.62K Sell
1,505
-519
-26% -$3.35K ﹤0.01% 2305
2025
Q1
$13.6K Buy
2,024
+519
+34% +$4.8K ﹤0.01% 2137
2024
Q4
$14.2K Sell
1,505
-454
-23% -$4.72K ﹤0.01% 2163
2024
Q3
$20.9K Hold
1,959
﹤0.01% 2139
2024
Q2
$19.9K Hold
1,959
﹤0.01% 2032
2024
Q1
$23K Buy
+1,959
New +$25.1K ﹤0.01% 1995
2023
Q3
Sell
-24,431
Closed -$307K 1098
2023
Q2
$307K Buy
24,431
+454
+2% +$5.39K ﹤0.01% 767
2023
Q1
$266K Buy
23,977
+1,272
+6% +$15.7K ﹤0.01% 798
2022
Q4
$277K Buy
22,705
+2,005
+10% +$22.6K ﹤0.01% 698
2022
Q3
$216K Sell
20,700
-149
-0.7% -$1.66K ﹤0.01% 853
2022
Q2
$224K Sell
20,849
-4,038
-16% -$33.3K ﹤0.01% 862
2022
Q1
$235K Buy
+24,887
New +$233K ﹤0.01% 912
2021
Q3
Sell
-22,146
Closed -$214K 962
2021
Q2
$214K Buy
22,146
+1,195
+6% +$11.7K ﹤0.01% 984
2021
Q1
$207K Buy
+20,951
New +$324K ﹤0.01% 987

Other funds holding FOLD

CIBC Private Wealth Group's FOLD Position: Q4 2025 in Review

CIBC Private Wealth Group sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 1,505 shares — an estimated $11.9K sold.

CIBC Private Wealth Group first reported a position in FOLD in Q1 2021 and held it in 15 quarters. The position peaked at $307K in Q2 2023. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • CIBC Private Wealth Group reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 1,505 Amicus Therapeutics shares in Q4 2025, an estimated $11.9K.
  • CIBC Private Wealth Group first reported a position in Amicus Therapeutics in Q1 2021 and held it in 15 quarters.
  • CIBC Private Wealth Group's Amicus Therapeutics position peaked at $307K in Q2 2023.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.